Sermorelin growth studies
The childhood research measured height. Adult enthusiasm often starts somewhere else.
Height velocity
Centimeters per year give the sermorelin record a useful solidity. In a multicenter trial of prepubertal children with growth hormone deficiency, first-year height velocity rose from about 4.1 cm/year to roughly 7-8 cm/year, without excessive IGF-1 generation. These children had a defined growth disorder. The outcome answered a question about their growth.
I trust this result for the question it investigated. The trouble begins when that childhood record becomes background reassurance for adult vitality or cosmetic claims. An adult's sleep, recovery or fat distribution would need to be measured directly. The children cannot answer on their behalf.
The 14-day adult study
Ten healthy older men were compared with nine young men in a 14-day study. GHRH(1-29) produced dose-related increases in 24-hour GH and IGF-1. At the higher study dose, the hormone parameters no longer differed significantly from those of the young men; fasting glucose did not change.
The result explains much of sermorelin's appeal. A diminished hormone response could be stimulated again. The parallel with the childhood result explains the appeal. The adult experiment, however, measured hormones over a short interval. It supplies no long-term answer about adult strength, independence or well-being.
Peptide clearance and GH duration
Sermorelin corresponds to the first 29 amino acids of GHRH and retains full activity at its receptor. It stimulates the pituitary's own GH release, with somatostatin and IGF-1 feedback still operating, as the GHRH pharmacology review explains.
The peptide's disappearance from blood and the hormone response run on different clocks. In 30 healthy men studied after intravenous or intranasal administration, GH stayed elevated for about three hours despite rapid peptide clearance; intranasal bioavailability was only about 3-5%. The mismatch between the peptide clock and the GH clock offers a useful starting point for comparison. The CJC-1295 comparison takes it further.
Anecdotal sleep accounts
The physiological case for adult sermorelin was made in an editorial. The caution about treating aging with secretagogues was also an editorial. Neither turns the short adult experiments into a long-term wellness trial.
Reports of vivid dreams, better sleep, recovery and gradual fat loss are anecdotal accounts, not clinical evidence. People also describe disappointment, redness or itching at an injection site, headaches, flushing, puffiness and occasional tingling. Their frequency and attribution remain uncertain. Those sleep stories leave an open question about efficacy: the controlled adult evidence here measures something else.
Approval, compounding and safety
Sermorelin was formerly FDA-approved for idiopathic growth hormone deficiency and short stature in children; the branded product left the U.S. market in 2008 for commercial reasons. It is treated as a Category 1 bulk substance under FDA's interim Section 503A policy, with final guidance issued January 2025. The compounded form of sermorelin has no FDA approval.
Growth hormone can oppose insulin action, and chronically raised GH and IGF-1 bring unresolved growth-related safety concerns. The review of GHRH biology and therapeutic development provides the broader context. Large, long-term trials of adult anti-aging use remain absent. Sermorelin is also prohibited in sport under WADA S2. A former childhood indication settles a much smaller question than the adult reputation suggests.